What is HC Wainwright’s Estimate for AUTL FY2025 Earnings?

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) – Research analysts at HC Wainwright issued their FY2025 earnings per share estimates for shares of Autolus Therapeutics in a report issued on Tuesday, February 17th. HC Wainwright analyst E. Bodnar forecasts that the company will earn ($1.04) per share for the year. HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Autolus Therapeutics’ current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Autolus Therapeutics’ Q4 2025 earnings at ($0.30) EPS, Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.27) EPS, FY2027 earnings at ($0.83) EPS, FY2028 earnings at ($0.64) EPS and FY2030 earnings at ($0.24) EPS.

A number of other equities research analysts have also recently issued reports on AUTL. Weiss Ratings reiterated a “sell (d-)” rating on shares of Autolus Therapeutics in a research note on Wednesday, January 21st. Wall Street Zen downgraded shares of Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 15th. Zacks Research downgraded shares of Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, January 21st. Finally, Needham & Company LLC decreased their price objective on Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a report on Monday, January 12th. Five equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $8.50.

Autolus Therapeutics Stock Up 3.3%

NASDAQ AUTL opened at $1.56 on Wednesday. The company has a market capitalization of $415.18 million, a PE ratio of -1.88 and a beta of 1.98. The firm’s 50 day moving average is $1.57 and its 200-day moving average is $1.57. Autolus Therapeutics has a 12-month low of $1.11 and a 12-month high of $2.70.

Institutional Investors Weigh In On Autolus Therapeutics

Several large investors have recently made changes to their positions in AUTL. Tudor Investment Corp ET AL boosted its position in shares of Autolus Therapeutics by 36.5% in the fourth quarter. Tudor Investment Corp ET AL now owns 282,113 shares of the company’s stock valued at $561,000 after acquiring an additional 75,460 shares during the period. Armistice Capital LLC grew its stake in shares of Autolus Therapeutics by 12.2% in the fourth quarter. Armistice Capital LLC now owns 17,500,000 shares of the company’s stock worth $34,825,000 after purchasing an additional 1,900,000 shares during the last quarter. Cetera Investment Advisers lifted its position in shares of Autolus Therapeutics by 37.3% in the 4th quarter. Cetera Investment Advisers now owns 1,099,750 shares of the company’s stock worth $2,189,000 after purchasing an additional 298,500 shares during the period. Mak Capital One LLC grew its position in shares of Autolus Therapeutics by 15.3% in the 4th quarter. Mak Capital One LLC now owns 30,005,343 shares of the company’s stock worth $59,711,000 after buying an additional 3,987,727 shares during the period. Finally, The Manufacturers Life Insurance Company raised its stake in Autolus Therapeutics by 29.8% during the fourth quarter. The Manufacturers Life Insurance Company now owns 49,864 shares of the company’s stock valued at $99,000 after buying an additional 11,445 shares during the last quarter. 72.83% of the stock is owned by hedge funds and other institutional investors.

Autolus Therapeutics News Roundup

Here are the key news stories impacting Autolus Therapeutics this week:

• Positive Sentiment: HC Wainwright initiated coverage with a “Buy”/”Strong-Buy” and a $9.00 price target — a very large implied upside versus the current share price; this kind of initiation can attract momentum buyers and re-rate sentiment for a beaten-down biotech. Read More.
• Positive Sentiment: HC Wainwright published detailed EPS forecasts across FY2025–FY2030 and quarter-level EPS estimates (showing shrinking losses over time), reinforcing their view that Autolus’ pipeline and commercialization path could improve economics over the next several years — supportive for long-term bulls. Read More.
• Neutral Sentiment: Short-interest data for mid-February in the report appears to show zeros/NaN (likely a reporting anomaly) and therefore does not provide clear evidence of elevated short pressure driving the move.
• Negative Sentiment: Risks remain — the $9 target implies very large upside and may be optimistic given current cash burn, clinical/regulatory uncertainties and likely need for future financing; those factors could dilute shareholders or cause volatility if progress stalls.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.